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ReviewActivation of Nuclear Receptors:
A Perspective from Structural Genomics
olism of glucose, lipids, and xenobiotics (Chawla et al.,
2001).
All nuclear receptors contain at least one of the two
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Van Andel Research Institute
333 Bostwick Avenue highly conserved domains: the centrally located DNA
binding domain (DBD) and the C-terminal ligand bindingGrand Rapids, Michigan 49503
2 Discovery Research domain (LBD). The LBD plays a pivotal role in ligand-
mediated signaling. In addition to ligand recognition,GlaxoSmithKline
Research Triangle Park, North Carolina 27709 the LBD contains dimerization motifs and a ligand-
dependent activation function, which requires the
proper position of the activation helix (the AF-2 helix,
or helix 12) located at the C-terminal end of the receptor.
Crystal structures of more than two dozen different When bound to an activating ligand, the AF-2 helix is
nuclear receptor ligand binding domains have defined stabilized in the active conformation, which allows the
a simple paradigm of receptor activation, in which LBD to recruit coactivator proteins such as steroid re-
agonist binding induces the activation function-2 (AF-2) ceptor coactivators (SRC-1, 2, and 3) and the TRAP/
helix to form a charge clamp for coactivator recruit- DRIP mediator complex to activate target promoters. In
ment. Recent structural studies present a surprising contrast, the binding of an antagonist destabilizes the
contrast. Activation of the mouse LRH-1 receptor is AF-2 helix from the active conformation and promotes
independent of a bound agonist despite its large ligand the recruitment of corepressors such as nuclear core-
binding pocket, whereas the activation of the Dro- pressor (N-CoR) and silencing mediator for retinoid and
sophila DHR38 receptor is dependent on ecdysteroids thyroid hormone receptors (SMRT) to repress transcrip-
even though the receptor lacks a ligand binding tion (Rosenfeld and Glass, 2001). Because ligand bind-
pocket. These new findings shed light on the diverse ing and ligand-mediated cofactor recruitment are crucial
structural mechanisms that nuclear receptors have for functions mediated by nuclear receptors, the LBD
evolved for activation, and have important implications has been the focus of intense structural study.
in their respective signaling pathways.
Structural Genomics of LBDsThe complete human genome contains 48 nuclear re-
The nuclear receptor superfamily has been grouped intoceptors that include receptors for classic endocrine li-
six subfamilies based on sequence alignment and phylo-gands such as steroid hormones, retinoic acids, vitamin
genetic tree construction (NRNC, 1999). Since the firstD, and thyroid hormone (Table 1). These classic recep-
set of LBD structures of the apo-RXR and ligand-boundtors are DNA binding and ligand-dependent transcrip-
RAR and TR were published in 1995 by the Moras andtional factors that modulate gene expression involved
Fletterick groups (Bourguet et al., 1995; Renaud et al.,in a broad spectrum of physiology. One distinguishing
1995; Wagner et al., 1995), more than two dozen LBDfact about these classic receptors is that they are among
structures have been determined for the classic recep-the most successful molecular targets in the history of
tors and the adopted orphan receptors (Table 1). Thedrug discovery. Every receptor has one or more cognate
structures of the Drosophila DHR38 (NR4A4, a homologsynthetic ligands currently being used as medicines.
of the mammalian NGFI-B/Nurr1 receptors) and theThe human nuclear receptors also include a class of
mouse LRH-1, published in the current issues of Cell andorphan receptors for which no ligand was known when
Molecular Cell, together with the Nurr1 LBD structurethe receptor was cloned, such as liver receptor homolog
recently published in Nature, not only expand the list of1 (LRH-1, or NR5A2/FTF/PHR) and the nerve growth
the LBD structures but also are the first representativesfactor-induced clone B (NGFI-B) receptors. Given the
of their respective subfamilies (NR4 and NR5), whichprominent role of the classic receptors in physiology
still remain as orphan receptors to date (Baker et al.,and their successes as drug targets, there has been
2003; Sablin et al., 2003; Wang et al., 2003). If we assumeenormous interest from both academia and the pharma-
that the 48 human receptors can be divided into 28ceutical industry in pursuing orphan receptors as drug
subsets based on their ligand binding similarity (Willsontargets. The result of intense research in the past few
and Moore, 2002), LBD structures have been determinedyears has been the emergence of a class of so-called
for two thirds of these subsets (Table 1), which include“adopted” orphan receptors for which either natural or
representative structures from every subfamily of recep-synthetic ligands have been identified. In turn, these
tors except for the Dax/SHP subfamily. These structuresnewly identified ligands have been exploited as chemi-
are obtained with various LBDs in complex with agonistscal tools to elucidate the biology through the approach
or antagonists, some with fragments of coactivators orof “reverse endocrinology” (Kliewer et al., 1999), and
corepressors, and in the form of monomers, dimers,have established the equally important role of these
or tetramers. The rich information provided by theseorphan receptors in physiology, especially in the metab-
structures has made it possible to develop a global view
of the molecular basis of ligand binding and ligand-
mediated regulation of nuclear receptors.*Correspondence: eric.xu@vai.org
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Table 1. Human Nuclear Receptors and the Solved LBD Structures
Classic Receptors Structurea Adopted Orphan Receptors Structure Orphan Receptors Structure
AR  CAR  COUP-TF (I, II, III) 
ER (, )  ERR (, , )  DAX 
GR  FXR  GCNF 
MR  HNF4 (, )  LRH b
PR  LXR (, )  NGFI-B (, , ) c
RAR (, , )  PPAR (, , )  PNR 
TR (, )  PXR  RevErbA 
VDR  ROR (, , )  SF1 
RXR (, , )  SHP 
TLX 
TR2, TR4 
a A “” indicates the LBD structure for at least one of the subtypes is solved; a “” indicates the structure is unsolved.
b The structure determined is mouse LRH-1.
c The structures determined are Drosophila DHR38 and human Nurr1.
All nuclear receptor LBD structures determined to in the DHR38 receptor to 1400 A˚3 in the subtypes of
proxisome proliferator-activated receptors (PPARs).date contain 11–13  helices that are arranged into a
three-layer antiparallel -helical sandwich (Figure 1). The trend seems that the adopted orphan receptors
such as PPARs and pregnane X receptor (PXR) containThe three long helices (helices 3, 7, and 10) form the
two outer layers of the sandwich. The middle layer of a large ligand binding pocket, whereas the classic re-
ceptors have a smaller pocket. This variation seemshelices (helices 4, 5, 8, and 9) is present only in the top
half of the domain but is missing from the bottom half, to be consistent with the biology mediated by these
receptors. The large pockets in PXR and the PPARsthereby creating a cavity for ligand binding in most of
the receptors. The C-terminal activation region also allow these receptors to bind to diverse metabolites
promiscuously and with a low affinity. In contrast, theforms an  helix (AF-2), which can adopt multiple confor-
mations depending on the nature of the bound ligand. small pocket in the classic receptors limits these recep-
Structural comparison reveals that the top half of the tors to recognize a specific ligand with a high affinity.
domain is highly similar among various LBDs, sug- Such high affinity and specificity of ligand recognition
gesting that the helix sandwich fold is evolutionarily may be required for these classic receptors to mediate
selected for the binding of small molecules in most re- their physiological pathways.
ceptors. The specificity of ligand binding is also determined
by the shape of the ligand binding pocket, which also
varies greatly from receptor subtype to subtype, to ac-Structural Basis of Ligand Recognition
commodate a variety of functions mediated by theseThe first step of nuclear receptor activation is initiated
receptors. The large pocket seen in PPARs has a distinctby ligand binding, and thus the ligand binding pocket
three-arm Y shape, allowing it to bind ligands with multi-is an important structural feature of nuclear receptors.
ple branches (such as phospholipids and synthetic fi-The ligand binding pocket is generally located behind
brates), or to bind singly branched ligands, such ashelix 3 and in the front of helices 7 and 10 (cyan surfaces
fatty acids, in multiple conformations (Xu et al., 1999).in Figure 1). Despite the conserved fold of LBDs, the
ligand binding pocket varies greatly in size, from 30 A˚3 In contrast, PXR has an elliptical shaped pocket with a
Figure 1. Overall Structures and Ligand Binding Pockets of Nuclear Receptor LBDs
The LBDs of PPAR, PXR, GR, LRH-1, and DHR38 are illustrated by ribbons and their ligand binding pockets are presented in cyan surfaces.
The C-terminal AF-2 helix is colored in red and the TIF2 LXXLL motif in the GR structure is colored in green.
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GR LBD structure reveals that the GR pocket has
evolved to form specific hydrogen bonds with every
polar group of dexamethasone, which has an identical
set of polar groups as the endogenous glucocorticoid
cortisol. Structural comparison reveals that such a com-
plete set of hydrogen bonds between GR and dexameth-
asone cannot be constructed in steroid receptors other
than GR because of a different distribution of polar
atoms in the pocket surface. The situation is even more
dramatic between AR and ER, where the only major
difference in their respective hormones is a C3 ketone
in testosterone versus a C3 hydroxyl in estradiol. In AR,
the C3 ketone of testosterone accepts two hydrogen
bonds from residues Q711 and R752, which are also
conserved in GR and PR. In ER, the corresponding argi-
nine is conserved but the corresponding glutamine resi-
Figure 2. Structural Comparison of the PPAR LBD Bound to an
due is a glutamate, which prefers to accept a hydrogenSRC-1 Coactivator Motif or an SMRT Corepressor Motif
bond from the C3 position of the ligand. The replacement
The surface of the PPAR LBD, excluding the AF2 helix, is shown
of glutamine by glutamate therefore explains the selec-in white. The AF-2 helix is in red and the charge clamp lysine from
tivity of ER for a hydroxyl group at the C3 position, whichhelix 3 is in blue.
also serves as hydrogen bond donor to the correspond-
ing arginine residue. Taken together, nuclear receptors
have evolved remarkably down to the single-residuevolume of 1200 A˚3, allowing it to bind to the cholesterol-
level to recognize specific ligands by changing the size,lowering drug SR12813 in three different conformations
shape, and polar/nonpolar nature of their ligand binding(Watkins et al., 2001). Although the PXR pocket is smaller
pockets.than the PPAR pocket, the conformational flexibility of
PXR apparently allows the pocket to expand to accom-
modate larger ligands, such as hyperforin and the antibi- Ligand-Mediated Activation versus Repression
The second step of nuclear receptor activation is ligand-otic rifampicin, the largest ligand known for any nuclear
receptor. The spherical feature and the plasticity of the induced recruitment of coactivator complexes, which
contain chromatin-modifying enzymes required for tran-PXR pocket have thus allowed this receptor to serve
as the key regulator in response to binding of diverse scription. Nuclear coactivators such as SRC-1 contain
multiple LXXLL motifs that interact with LBDs. X-rayxenobiotic chemicals, which do not come with the same
shape or the same hydrogen-bonding groups. structures of various LBDs bound to agonists and pep-
tides with LXXLL motifs reveal a conserved mode ofBesides the size and shape, the hydrophobic/hydro-
philic nature of the pocket surface also plays a determin- coactivator binding. In these structures, the LXXLL bind-
ing pocket comprises two parts: the constant part (heli-ing role in ligand binding specificity. This is exemplified
by the steroid hormone receptors GR, AR, PR, and ER ces 3, 3, 4, and 5) and the variable part (AF-2 helix).
The constant part adopts essentially the same confor-(Bledsoe et al., 2002). These receptors share a high degree
of sequence identity and similar three-dimensional struc- mation in all the LBD structures, and does not change
with the binding of different ligands. In contrast, thetures, yet they are able to distinguish between several
very similar endogenous steroid hormones to mediate AF-2 helix adopts different conformations, depending
on the nature of the bound ligand. As seen in the struc-their dramatically different physiological functions. The
Figure 3. Conservation of the Charge Clamp Pocket
Sequence alignment of cofactor binding pockets in nuclear receptors reveals the conserved nature of the charge clamp pocket and the AF-2
helix. Positively charged residues are labeled in blue, negatively charged residues are in red, polar residues are in green, and the hydrophobic
residues are in black. The arrows indicate the positions of the charged clamp residues.
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ture of PPAR, when bound with an activating ligand, have explored a variety of structural mechanisms to
stabilize the AF-2 helix in the active state. The mostthe AF-2 helix is packed against helices 3 and 10, be-
coming an integral body of the LBD (Xu et al., 2001). In straightforward mechanism is direct interaction be-
tween the AF-2 helix and the bound ligand, as seen inthis active conformation, a highly conserved glutamate
residue from the AF-2 helix, together with a lysine resi- the structures of PPARs and GR. In PPARs, diverse
activating ligands contain an acidic group such as car-due from the end of helix 3, forms a charge clamp pocket
to interact with the coactivator motifs (Figure 2). boxylate or thiazolidinedione (TZD), which forms a direct
hydrogen bond with the AF-2 helix and locks this helixThe LXXLL coactivator motif adopts a two-turn  helix
with its three-leucine side chains fitting into the hy- into the active conformation (Gampe et al., 2000a). In
GR, the active AF-2 helix is stabilized by hydrophobicdrophobic pocket between the two charge clamp resi-
dues, which further stabilize the coactivator helix by interactions with the bound dexamethasone (Bledsoe
et al., 2002). However, in many LBD/agonist complexes,capping both helical ends. The high degree of amino
acid sequence conservation in the coactivator binding the bound ligand does not make any direct contact with
the AF-2 helix; instead, the ligand induces a conforma-pocket suggests that this mode of coactivator binding
represents a general mechanism for the activation of tional change in the receptor that allows a stable docking
of the AF-2 helix. The most dramatic example of thisnuclear receptors (Figure 3). In addition, nuclear recep-
tors can achieve specific recognition of coactivators by mechanism is seen in the RXR structure. The apo-RXR
forms a stable tetramer that is incompetent for bindinginteracting with the variable residues within or flanking
the LXXLL motifs. In the case of GR, the specific recogni- of coactivators (Gampe et al., 2000b). Binding of 9-cis-
retinoic acid induces a dramatic conformational changetion of the TIF2 third LXXLL motif is mediated by two
additional charge residues of GR that form a second that results in dissociation of the tetramer and formation
of active dimers that are capable of binding coactivatorscharge clamp to interact with the charge residues spe-
cific to the TIF2 third motif (Bledsoe et al., 2002). (Gampe et al., 2000a). Ligand-induced conformational
changes are also seen in ER, where antagonist bindingOn the other hand, the position of the AF-2 helix also
plays a key role in recruiting corepressors such as partially unwinds helices 3 and 10. By comparison, ago-
nists appear to stabilize helices 3 and 10, which allowsN-CoR and SMRT. These nuclear corepressors bind to
LBDs via a conserved LXXXIXXXL/I motif, which is simi- the active AF-2 helix to pack tightly against these two
helices (Brzozowski et al., 1997; Shiau et al., 1998). Thelar to the LXXLL coactivator motif but has an N-terminal
extension. In comparison to coactivators, the longer co- third mechanism is that the AF-2 helix is predisposed
in the active conformation, and the regulation of theserepressor motif adopts a three-turn  helix instead of
two turns for the coactivator motif, and binds to the receptors is mediated primarily through negative mech-
anisms. ERR contains a small ligand binding pocket,same overlapped site as for the LXXLL helix (Xu et al.,
2002). The additional turn of the corepressor helix ex- and its AF-2 helix is constantly held in the active confor-
mation by inserting a hydrophobic phenylalanine fromtends into space that would normally be occupied by
the AF-2 helix when it is in the active conformation. this helix into its small pocket (Greschik et al., 2002).
The binding of ERR antagonists (diethylstilbestrol orThus the binding of corepressors and the active AF-2
conformation is mutually exclusive. The AF-2 helix must 4-hydroxytamoxifen) inactivates the receptor by rear-
ranging the AF-2 helix from the active conformation. Inshift to some alternative position to accommodate the
larger corepressor helix. In the case of PPAR, re- HNF4, the bound palmitic acid serves as a nonex-
changeable cofactor that stabilizes the AF-2 helix inarrangement of the AF-2 helix is achieved by an antago-
nist, which pushes the AF-2 helix from its active position active position (Dhe-Paganon et al., 2002; Wisely et al.,
2002). Regulation of HNF4 activity could be mediatedto provide additional space for binding of the corepres-
sor helix. The rearrangement of the AF-2 helix from its through posttranslational modifications such as phos-
phorylation and acetylation, which would control nu-active position also allows the corepressor helix to dock
closer into the charge clamp pocket. The binding mode clear retention of the protein (Soutoglou et al., 2000).
The recent DHR38 and LRH-1 structures have addedof corepressors, similar to that of coactivators, is also
highly conserved among nuclear receptors (Figure 3). It further complexity to these mechanisms and raised
questions about the role of ligand binding. The activationseems clear that binding of coactivators and corepres-
of both DHR38 and LRH-1 apparently still requires thesors is tightly modulated by the position of the AF-2
precise positioning of the AF-2 helix in the active confor-helix. The conformational flexibility of this helix allows
mation despite the dramatic contrast in their ligand re-it to sense the presence of the bound ligand, either an
quirements. LRH-1 is a true orphan receptor that playsagonist or an antagonist, and to recruit the coactivators
key roles in homeostasis of bile acids and cholesterolor corepressors that ultimately determine the transcrip-
(Goodwin et al., 2000; Lu et al., 2000). Whereas mosttional output of nuclear receptors.
nuclear receptors bind to DNA as dimers, LRH-1 binds
to DNA and activates transcription as a monomer. Sablin
Multiple Mechanisms of Nuclear et al. (2003) present a crystal structure of the mouse
Receptor Activation LRH-1 LBD that has set up a framework for understand-
A common mechanism for activation of nuclear recep- ing monomeric action of LRH-1.
tors is mediated through the precise positioning of the However, the most surprising aspect of the structure
AF-2 helix, which then forms a charge clamp pocket for is the presence of a large (800 A˚3), completely en-
the recruitment of coactivators. Within the framework closed, ligand binding pocket in the LRH-1 LBD. Al-
though there is no ligand in the pocket, the AF-2 helixof this general mechanism, however, nuclear receptors
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is in the active conformation, in good agreement with AF-2 helix is required for its activation, it does not form
a conventional charge clamp pocket for coactivator re-the constitutive activation phenotype of LRH-1. Radical
mutations that change the size or the shape of the pocket cruitment. The conserved glutamate in the AF-2 helix
from other nuclear receptors is replaced by an aspara-do not reduce the activation potential of the receptor,
suggesting that the endogenous ligands (if they exist) gine in DHR38 and a lysine in the NGFI-B/Nurr1 recep-
tors, and the conserved lysine at the end of helix 3 iscan change shape and size to fit into the mutated recep-
tors, or that there are no such ligands at all. replaced by a glutamate. It seems that NGFI-B contains
a “reverse” charge clamp, but the topology of the re-How does the receptor stabilize the AF-2 helix in the
presence of a large empty cavity inside the domain? verse charge clamp pocket is altered too dramatically
to accommodate an inverted LXXLL motif. Reversal ofThe LRH-1 structure reveals a four-layer helix sandwich
instead of the three-layer sandwich observed for other the reverse charge clamp in Nurr1 also fails to rescue
the binding of LXXLL motif (Wang et al., 2003). In fact,nuclear receptors. The additional layer of helix is com-
posed of a long helix 2 that packs tightly alongside helix no known coactivators have been shown to bind to
DHR38 or NGFI-B/Nurr1. However, there must be a3. The interactions with helix 2 would tend to stabilize
helix 3, in a manner similar to that observed with ER, DHR38 coactivator given the requirement of its AF-2
helix for its activation. What is it? If such a putativethus creating a stable docking surface for the AF-2 helix.
The constitutive activation of LRH-1 is analogous to coactivator exists, it must be highly conserved because
the insect DHR38 is highly homologous to the mamma-ERR and HNF4. However, in this case, evolution has
designed a delicate negative system through the binding lian NGFI-B receptors. Given the importance of NGFI-B
receptors in the survival of dopaminergic neurons andof SHP, which represses LRH-1 activation in response
to activation of another nuclear receptor, FXR (Goodwin the development of Parkinson’s disease (Zetterstrom et
al., 1997), the pursuit of the putative DHR38/NGFI-B-et al., 2000; Lu et al., 2000). In addition, the presence
of the large empty pocket in LRH-1 not only raises the specific coactivator is particularly pressing for elucida-
tion of the atypical DHR38/NGFI-B signaling pathway,question of why nature designs such a pocket with no
corresponding ligand, but also tempts structural chem- for which many questions remain to be addressed.
ists to design small molecules to dock into this pocket
to achieve “super” activation. The feasibility of these Perspectives
artificial ligands as pharmaceutical agents, either desta- Crystal structures for more than half of the human nu-
bilizing or further stabilizing the AF-2 helix, remains to clear receptors have been determined. These structures
be seen. reveal that nuclear receptors have evolved from a con-
In the case of DHR38, Baker et al. (2003) have discov- served sandwich fold to achieve specific recognition
ered a series of ecdysteroid derivatives that activate of diverse hormones and ligands. The structures also
transcription through the receptor, some with potency highlight the conformational flexibility of the AF-2 helix
two orders of magnitude better than that on the well- and how nuclear receptors explore this helix, in a variety
characterized ecdysone receptor. Although the physio- of mechanisms, to sense diverse ligands and to cascade
logical relevance of DHR38 activation in insect morpho- the signal from ligand binding to transcriptional regula-
genesis remains to be established, the authors have tion. Currently, there is only one classic receptor (MR)
revealed several intriguing and puzzling aspects of and one adopted orphan receptor (CAR) for which the
DHR38 activation. DHR38 is the first receptor known LBD structure remains unsolved. In contrast, the struc-
whose activation requires the preactivated heterodimer tures of most orphan receptors remain unknown (Table
partner, either USP in insect or RXR in mammals. This 1). As much as the surprise we learned from DHR38,
is completely different from the activation of other RXR Nurr1, and LRH-1, the excitement for the structures of
heterodimer complexes. For example, activation of PPAR/ the remaining orphan receptors is yet to come.
RXR heterodimer only requires the PPAR AF-2 helix
Acknowledgmentsand its ligands (Schulman et al., 1998). The RXR ligand
and its AF-2 helix are dispensable for the activation of
The authors thank David Nadziejka for editorial assistance.the PPAR/RXR heterodimer although the addition of
an RXR agonist can synergistically activate the receptor.
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